Zota Health Care Ltd. (IN:ZOTA)
:ZOTA
Top Page
Zota Health Care Ltd.
(ZOTA)
Select Model
Select Model
Rating:41Neutral
Price Target:
₹1,100.00
▼(-28.25% Downside)
Action:ReiteratedDate:01/23/26
The score is weighed down primarily by weak financial performance—loss-making operations and negative operating/free cash flow despite strong revenue growth. Technicals add further pressure with price below key moving averages and a negative MACD. Valuation is mixed: a high dividend yield helps, but a negative P/E reflects ongoing losses.
Positive Factors
Strong Revenue Growth
Sustained high revenue growth expands market presence and provides scale benefits: it can fund capacity, R&D and distribution investments over months. If maintained, top-line momentum underpins the company’s ability to pursue market share and long-term product commercialization.
Negative Factors
Negative Profitability
Persistently negative margins imply core profitability issues: costs and operating inefficiencies are outpacing revenue gains. Over the medium term, continued losses impair retained earnings, limit reinvestment capacity, and raise the bar for management to convert sales growth into sustainable profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained high revenue growth expands market presence and provides scale benefits: it can fund capacity, R&D and distribution investments over months. If maintained, top-line momentum underpins the company’s ability to pursue market share and long-term product commercialization.
Read all positive factors
Zota Health Care Ltd. (ZOTA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹37.12B
Dividend Yield0.06%
Average Volume (3M)68.23K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth82.58%
EPS Growth-63.05%
CountryIN
Employees445
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.90
Shares Outstanding30,332,655
10 Day Avg. Volume83,032
30 Day Avg. Volume68,228
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)10.00
Price to Sales (P/S)7.63
P/FCF Ratio-23.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-15
Revenue Forecast (FY)₹11.03B
Zota Health Care Ltd. Business Overview & Revenue Model
Company Description
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India. It offers generic drugs, over-the-counter products, ayurvedic products, and nutraceutical products. The company provides various medicines for chronic i...
How the Company Makes Money
Zota Health Care primarily makes money by selling pharmaceutical products and related healthcare offerings to distributors, hospitals, pharmacies, and other institutional/retail channels in India and in export markets. Key revenue streams typicall...
Zota Health Care Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
44
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.98B | 2.93B | 1.80B | 1.40B | 1.31B | 1.07B |
| Gross Profit | 1.09B | 1.56B | 803.38M | 310.68M | 418.86M | 193.14M |
| EBITDA | 58.61M | -36.65M | 81.21M | 98.05M | 164.26M | 28.63M |
| Net Income | -475.21M | -563.98M | -143.48M | -57.73M | 89.08M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 6.06B | 4.39B | 2.28B | 1.58B | 1.39B | 854.69M |
| Cash, Cash Equivalents and Short-Term Investments | 63.18M | 36.19M | 10.05M | 11.15M | 22.99M | 13.46M |
| Total Debt | 1.81B | 1.40B | 952.85M | 451.22M | 149.00M | 0.00 |
| Total Liabilities | 2.87B | 2.12B | 1.38B | 777.55M | 494.67M | 191.72M |
| Stockholders Equity | 3.16B | 2.24B | 899.77M | 803.57M | 896.27M | 662.97M |
Cash Flow | ||||||
| Free Cash Flow | -558.29M | -959.42M | -226.94M | -145.05M | 100.84M | -28.18M |
| Operating Cash Flow | -191.07M | -499.64M | -59.84M | -20.06M | 133.32M | -8.90M |
| Investing Cash Flow | -728.26M | -956.20M | -129.03M | 147.03M | -266.52M | 38.20M |
| Financing Cash Flow | 946.32M | 1.47B | 187.76M | -138.81M | 142.73M | -24.19M |
Zota Health Care Ltd. Technical Analysis
Negative
1533.20
Price Trends
1230.80
Negative
1383.62
Negative
1352.12
Negative
Market Momentum
-25.33
Negative
57.10
Neutral
85.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZOTA, the sentiment is Negative. The current price of 1533.2 is above the 20-day moving average (MA) of 1123.40, above the 50-day MA of 1230.80, and above the 200-day MA of 1352.12, indicating a neutral trend. The MACD of -25.33 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZOTA.
Zota Health Care Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹21.94B | 10.80 | ― | 2.36% | 16.53% | 4.37% | |
70 Outperform | ₹37.32B | 29.96 | ― | 0.13% | 11.91% | 36.92% | |
54 Neutral | ₹23.17B | -36.05 | ― | ― | -4.18% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹20.31B | 144.78 | ― | ― | 9.78% | 50.78% | |
49 Neutral | ₹18.20B | -18.14 | ― | 0.08% | -2.81% | -444.69% | |
41 Neutral | ₹37.12B | -40.91 | ― | 0.06% | 82.58% | -63.05% |
* Healthcare Sector Average
IN:ZOTA
Zota Health Care Ltd.
1,223.60
437.89
55.73%
IN:ALEMBICLTD
Alembic Limited
85.46
-10.34
-10.79%
IN:INDOCO
Indoco Remedies Limited
197.15
-33.24
-14.43%
IN:PANACEABIO
Panacea Biotec Limited
331.60
-120.20
-26.60%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
398.50
195.53
96.33%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
480.95
-29.15
-5.71%
Zota Health Care Ltd. Corporate Events
Zota Health Care Schedules Investor Meeting with Nirmal Bang
Feb 28, 2026
Zota Health Care Ltd. has announced that its officials will participate in an analyst and institutional investor conference organized by Nirmal Bang Institutional Equities on March 6, 2026, via video conference. The company will use existing busin...
Zota Health Care Launches ‘All Day Stores’ Retail Chain to Deepen Consumer Reach
Feb 28, 2026
Zota Health Care Ltd. has expanded its consumer-facing portfolio by launching a new national retail chain, All Day Stores, through its subsidiary Everyday Herbal Beauty Care Limited. The format will focus on private-label offerings spanning person...
Zota Health Care Grants Fifth ESOP Tranche to Employees
Feb 20, 2026
Zota Health Care Ltd. has granted 16,394 stock options to eligible employees under its Zota Health Care – Employee Stock Option Plan 2022, approved in line with SEBI’s share-based employee benefit regulations. The options, representing...
Zota Health Care Sets February 5 Earnings Call for Q3 FY26 Results
Jan 31, 2026
Zota Health Care Ltd. has scheduled an earnings conference call to discuss its financial performance for the third quarter and nine months ended December 31, 2025, following the planned announcement of results on February 4, 2026. The call, to be ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.